Genrix (Shanghai) Biopharmaceutical Co., Ltd. clinical trials
A subsidiary of Chongqing Genrix Biopharmaceutical Co., Ltd
The registry lists 28 studies whose lead sponsor is Genrix (Shanghai) Biopharmaceutical Co., Ltd.. 17 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2026.
- 28studies on the registry
- 17open to participants now
- 5phase 3 studies under way
- 5reach primary completion within a year
What it is testing
The drugs Genrix (Shanghai) Biopharmaceutical Co., Ltd.’s studies test, most open studies first — 5 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
5 of Genrix (Shanghai) Biopharmaceutical Co., Ltd.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- 2MMay
- 1JJun
- 2JJul
- AAug
- SSep
- OOct
- NNov
All 5
- May 2027A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.telikibart · Phase 3 · NCT07199257
- May 2027GR1803 Injection in Patients With Relapsed/Refractory Multiple MyelomaGR1803 · NCT06566547
- Jun 2027A Study of GR1803 in Systemic Lupus ErythematosusGR1803 · NCT07348055
- Jul 2027A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.GR2301 · NCT07647224
- Jul 2027GR1803 Injection in Patients With RRMMGR1803 · NCT06952075
Add all 5 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered1
- A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo.Nov 10, 2026NCT07930039
All 28 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 20
- 21
- 22
- 23
- 624
- 25
- 526
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.28 studies
Something wrong with this grouping? Tell us on the Chongqing Genrix Biopharmaceutical Co., Ltd page.
Studies
Recruiting first, then most recently updated. Showing 28 of 28. All Chongqing Genrix Biopharmaceutical Co., Ltd studies →
- A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo.Not yet recruitingNCT07930039Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.Not yet recruitingNCT07647224Phase 1
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With VitiligoNot yet recruitingNCT07647237Phase 1/2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07452198Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of GR1803 in Systemic Lupus ErythematosusRecruitingNCT07348055Phase 1/2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.Not yet recruitingNCT07199257Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy AdultRecruitingNCT07199270Phase 1
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.Not yet recruitingNCT07190716Phase 1
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic RhinitisRecruitingNCT07154342Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple MyelomaNot yet recruitingNCT07090954Phase 1/2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- GR1803 Injection in Patients With RRMMRecruitingNCT06952075Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe AsthmaRecruitingNCT06642961Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 InjectionRecruitingNCT06635798Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy AdultRecruitingNCT06313697Phase 1
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Phase III Study of GR1802 Injection in Patients With Atopic DermatitisNot yet recruitingNCT06216392Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.Not yet recruitingNCT06175143Phase 1
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingNCT06015243Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of GR1802 in Participants With Chronic Sinusitis With Nasal PolypsCompletedNCT06516302Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- GR1803 Injection in Patients With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06566547Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Phase I Trial of GR1803 Injection in Patients With RRMMCompletedNCT07102706Phase 1/2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).Active, not recruitingNCT06315426Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLEActive, not recruitingNCT06015230Phase 1/2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Study to Evaluate GR1801's Efficacy and SafetyCompletedNCT05846568Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal PolypsActive, not recruitingNCT05873803Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial SpondyloarthritisCompletedNCT05881785Phase 3
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- The Study of Single Dose Administration of GR2002 Injection in Chinese Health VolunteersCompletedNCT05954611Phase 1
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy AdultsCompletedNCT06302374Phase 1/2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial SpondyloarthritisCompletedNCT05162937Phase 2
Sponsor listed in the registry: Genrix (Shanghai) Biopharmaceutical Co., Ltd.